INT171888

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.38
First Reported 2001
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 13
Total Number 14
Disease Relevance 5.53
Pain Relevance 3.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Il1rn) extracellular region (Il1rn) nucleus (Il1rn)
lipid metabolic process (Il1rn) cytoplasm (Il1rn)
Anatomy Link Frequency
brain 2
Il1rn (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 53 100.00 Very High Very High Very High
rheumatoid arthritis 116 97.24 Very High Very High Very High
cytokine 169 96.12 Very High Very High Very High
long-term potentiation 16 95.44 Very High Very High Very High
Glutamate 9 94.80 High High
Inflammatory response 24 94.20 High High
Inflammation 172 90.00 High High
Hippocampus 40 87.80 High High
amygdala 7 85.12 High High
anakinra 6 84.08 Quite High
Disease Link Frequency Relevance Heat
Amnesia 16 99.32 Very High Very High Very High
Cognitive Disorder 137 98.76 Very High Very High Very High
Disease 159 98.00 Very High Very High Very High
Rheumatoid Arthritis 118 97.24 Very High Very High Very High
Systemic Lupus Erythematosus 2 96.36 Very High Very High Very High
Atherosclerosis 3 95.16 Very High Very High Very High
Mycobacterial Infection 17 94.36 High High
INFLAMMATION 213 93.84 High High
Alzheimer's Dementia 24 93.44 High High
Amyloid Plaque 8 88.96 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We therefore propose that these peptides mediate their effects on memory by binding to IRAP in specific brain nuclei.
IRAP Binding (binding) of in brain
1) Confidence 0.38 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604898 Disease Relevance 0.22 Pain Relevance 0.26
Suffice it to say, compounds unable to bind IRAP fail to inhibit its activity.


IRAP Neg (unable) Binding (bind) of
2) Confidence 0.38 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604898 Disease Relevance 0 Pain Relevance 0.03
Mutational studies reveal that the G428, A429 and N432 residues in IRAP are important for binding of both peptide substrates and inhibitors [40].
IRAP Binding (binding) of
3) Confidence 0.30 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604898 Disease Relevance 0 Pain Relevance 0.05
There are separate but overlapping collections of data that assess either competition binding to membrane fractions, or inhibition of IRAP catalytic activity; there is clear evidence that these two measures do not correlate.
IRAP Binding (binding) of
4) Confidence 0.30 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604898 Disease Relevance 0 Pain Relevance 0.03
Furthermore, Ang IV and LVV-H7 were found to be competitive inhibitors of IRAP, inhibiting its aminopeptidase activity by binding to the catalytic site [20,21].
IRAP Binding (binding) of
5) Confidence 0.30 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604898 Disease Relevance 0.26 Pain Relevance 0.27
These peptides bound specifically to the enzyme insulin-regulated aminopeptidase (IRAP), which is proposed to be the site in the brain that mediates the memory effects of these peptides.
IRAP Binding (bound) of in brain
6) Confidence 0.28 Published 2008 Journal BMC Neurosci Section Abstract Doc Link PMC2604898 Disease Relevance 0.17 Pain Relevance 0
In 2001, the specific target for Ang IV and LVV-H7 was identified – these peptides bind specifically, and with high affinity, to the transmembrane aminopeptidase IRAP [19].
IRAP Binding (bind) of
7) Confidence 0.26 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2604898 Disease Relevance 0.25 Pain Relevance 0.27
is normally achieved with the neutralizing action of endogenous IL-1Ra, which directly competes for binding to the receptor [29,30].
IL-1Ra Binding (binding) of
8) Confidence 0.16 Published 2010 Journal Crit Care Section Body Doc Link PMC2911722 Disease Relevance 0.67 Pain Relevance 0.26
Treatment with IL-1Ra provides a significant improvement in cognitive dysfunction, confirming the crucial role of IL-1?
IL-1Ra Binding (Treatment) of associated with cognitive disorder
9) Confidence 0.16 Published 2010 Journal Crit Care Section Body Doc Link PMC2911722 Disease Relevance 0.63 Pain Relevance 0.26
However, it is now understood that the choice of type I receptor was unfortunate because this soluble receptor has a high affinity for IL-1 receptor antagonist (IL-1ra), thus scavenging the endogenous IL-1 inhibitor.
IL-1ra Binding (affinity) of associated with antagonist
10) Confidence 0.04 Published 2001 Journal Arthritis Res Section Body Doc Link PMC128880 Disease Relevance 0.78 Pain Relevance 0.53
Understandably, polymorphisms in the genes encoding IL-1, its receptor, and IL-1RA have been found to be associated with a range of diseases including rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis and tuberculosis [57].
IL-1RA Binding (receptor) of associated with mycobacterial infection, atherosclerosis, rheumatoid arthritis, systemic lupus erythematosus and disease
11) Confidence 0.03 Published 2007 Journal J Inflamm (Lond) Section Body Doc Link PMC1838907 Disease Relevance 1.14 Pain Relevance 0.13
IL-1RA can also bind these receptors and acts as a competitive inhibitor.
IL-1RA Binding (bind) of
12) Confidence 0.02 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592774 Disease Relevance 0.91 Pain Relevance 0.42
IL-1ra competes for binding to the IL-1RI with IL-1?
IL-1ra Binding (binding) of
13) Confidence 0.01 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727904 Disease Relevance 0.26 Pain Relevance 0.30
The IL-1R antagonist (IL-1ra) is naturally occurring and binds to the IL-1RI.
IL-1ra Binding (binds) of associated with antagonist
14) Confidence 0.01 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727904 Disease Relevance 0.25 Pain Relevance 0.32

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox